263 related articles for article (PubMed ID: 19246562)
1. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
3. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL.
Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA
Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.
Tammam J; Ware C; Efferson C; O'Neil J; Rao S; Qu X; Gorenstein J; Angagaw M; Kim H; Kenific C; Kunii K; Leach KJ; Nikov G; Zhao J; Dai X; Hardwick J; Scott M; Winter C; Bristow L; Elbi C; Reilly JF; Look T; Draetta G; Van der Ploeg L; Kohl NE; Strack PR; Majumder PK
Br J Pharmacol; 2009 Nov; 158(5):1183-95. PubMed ID: 19775282
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
[TBL] [Abstract][Full Text] [Related]
6. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
7. Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss.
Medyouf H; Gao X; Armstrong F; Gusscott S; Liu Q; Gedman AL; Matherly LH; Schultz KR; Pflumio F; You MJ; Weng AP
Blood; 2010 Feb; 115(6):1175-84. PubMed ID: 20008304
[TBL] [Abstract][Full Text] [Related]
8. p16Ink4a or p19Arf loss contributes to Tal1-induced leukemogenesis in mice.
Shank-Calvo JA; Draheim K; Bhasin M; Kelliher MA
Oncogene; 2006 May; 25(21):3023-31. PubMed ID: 16407836
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibitory effect of rapamycin in Hodgkin-lymphoma cell lines characterized by constitutive NOTCH1 activation.
Nagy N; Hajdu M; Márk Á; Király PA; Tóth M; Dankó T; Csóka M; Sebestyén A
Tumour Biol; 2016 Oct; 37(10):13695-13704. PubMed ID: 27473087
[TBL] [Abstract][Full Text] [Related]
10. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
11. The anti-malarial drug chloroquine sensitizes oncogenic NOTCH1 driven human T-ALL to γ-secretase inhibition.
Hounjet J; Habets R; Schaaf MB; Hendrickx TC; Barbeau LMO; Yahyanejad S; Rouschop KM; Groot AJ; Vooijs M
Oncogene; 2019 Jul; 38(27):5457-5468. PubMed ID: 30967635
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the NOTCH and mTOR pathways by nelfinavir as a novel treatment for T cell acute lymphoblastic leukemia.
Chang YS; Gills JJ; Kawabata S; Onozawa M; Della Gatta G; Ferrando AA; Aplan PD; Dennis PA
Int J Oncol; 2023 Nov; 63(5):. PubMed ID: 37800623
[TBL] [Abstract][Full Text] [Related]
13. CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to gamma-secretase inhibitors.
Palomero T; Barnes KC; Real PJ; Glade Bender JL; Sulis ML; Murty VV; Colovai AI; Balbin M; Ferrando AA
Leukemia; 2006 Jul; 20(7):1279-87. PubMed ID: 16688224
[TBL] [Abstract][Full Text] [Related]
14. Activating Notch1 mutations in mouse models of T-ALL.
O'Neil J; Calvo J; McKenna K; Krishnamoorthy V; Aster JC; Bassing CH; Alt FW; Kelliher M; Look AT
Blood; 2006 Jan; 107(2):781-5. PubMed ID: 16166587
[TBL] [Abstract][Full Text] [Related]
15. Notch1 receptor regulates AKT protein activation loop (Thr308) dephosphorylation through modulation of the PP2A phosphatase in phosphatase and tensin homolog (PTEN)-null T-cell acute lymphoblastic leukemia cells.
Hales EC; Orr SM; Larson Gedman A; Taub JW; Matherly LH
J Biol Chem; 2013 Aug; 288(31):22836-48. PubMed ID: 23788636
[TBL] [Abstract][Full Text] [Related]
16. Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc.
Sharma VM; Calvo JA; Draheim KM; Cunningham LA; Hermance N; Beverly L; Krishnamoorthy V; Bhasin M; Capobianco AJ; Kelliher MA
Mol Cell Biol; 2006 Nov; 26(21):8022-31. PubMed ID: 16954387
[TBL] [Abstract][Full Text] [Related]
17. PSEN1-selective gamma-secretase inhibition in combination with kinase or XPO-1 inhibitors effectively targets T cell acute lymphoblastic leukemia.
Govaerts I; Prieto C; Vandersmissen C; Gielen O; Jacobs K; Provost S; Nittner D; Maertens J; Boeckx N; De Keersmaecker K; Segers H; Cools J
J Hematol Oncol; 2021 Jun; 14(1):97. PubMed ID: 34167562
[TBL] [Abstract][Full Text] [Related]
18. Synergistic antileukemic therapies in
Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
[TBL] [Abstract][Full Text] [Related]
19. Proteomics of resistance to Notch1 inhibition in acute lymphoblastic leukemia reveals targetable kinase signatures.
Franciosa G; Smits JGA; Minuzzo S; Martinez-Val A; Indraccolo S; Olsen JV
Nat Commun; 2021 May; 12(1):2507. PubMed ID: 33947863
[TBL] [Abstract][Full Text] [Related]
20. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia.
Sanda T; Li X; Gutierrez A; Ahn Y; Neuberg DS; O'Neil J; Strack PR; Winter CG; Winter SS; Larson RS; von Boehmer H; Look AT
Blood; 2010 Mar; 115(9):1735-45. PubMed ID: 20007543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
